High viral suppression and low attrition in healthy HIV-infected patients initiated on ART with CD4 above 500 cells/µL in a program setting in Uganda
暂无分享,去创建一个
M. Kamya | P. Byakika-Kibwika | P. Musinguzi | P. Kyambadde | I. A. Biraro | D. Byonanebye | F. Semitala | Irene Arinaitwe | J. Katende | A. Bakenga | Peter Kyambadde
[1] M. Siedner,et al. ART adherence and viral suppression are high among most non‐pregnant individuals with early‐stage, asymptomatic HIV infection: an observational study from Uganda and South Africa , 2019, Journal of the International AIDS Society.
[2] M. Petersen,et al. Factors predictive of successful retention in care among HIV-infected men in a universal test-and-treat setting in Uganda and Kenya: A mixed methods analysis , 2019, PloS one.
[3] N. McGrath,et al. Universal test and treat is not associated with sub‐optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial , 2018, Journal of the International AIDS Society.
[4] R. Wanyenze,et al. Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014–July 2015 , 2017, BMC Infectious Diseases.
[5] N. Ford,et al. Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring. , 2017, The Lancet. Infectious diseases.
[6] P. Vernazza,et al. Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades , 2016, BMJ Global Health.
[7] W. Andiman,et al. Frequent Episodes of Detectable Viremia in HIV Treatment-Experienced Children is Associated with a Decline in CD4+ T-cells Over Time. , 2016, Journal of AIDS & clinical research.
[8] W. Miller,et al. The HIV Care Continuum among Female Sex Workers: A Key Population in Lilongwe, Malawi , 2016, PloS one.
[9] C. Beyrer,et al. HIV treatment cascade in MSM, people who inject drugs, and sex workers , 2015, Current opinion in HIV and AIDS.
[10] H. Lane,et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.
[11] R. Salamon,et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.
[12] S. Karim. Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy , 2015 .
[13] D. Nash,et al. Risk factors for loss to follow-up prior to ART initiation among patients enrolling in HIV care with CD4+ cell count ≥200 cells/μL in the multi-country MTCT-Plus Initiative , 2015, BMC Health Services Research.
[14] T. Quinn,et al. Durable Suppression of HIV-1 after Virologic Monitoring-Based Antiretroviral Adherence Counseling in Rakai, Uganda , 2015, PloS one.
[15] W. Fawzi,et al. Predictors of Nonadherence to Antiretroviral Therapy among HIV-Infected Adults in Dar es Salaam, Tanzania , 2015, Journal of the International Association of Providers of AIDS Care.
[16] M. Boily,et al. Antiretroviral Therapy Uptake, Attrition, Adherence and Outcomes among HIV-Infected Female Sex Workers: A Systematic Review and Meta-Analysis , 2014, PloS one.
[17] D. Havlir,et al. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/&mgr;l in rural Uganda , 2014, AIDS.
[18] Jeffrey N. Martin,et al. CD4+ cell count at antiretroviral therapy initiation and economic restoration in rural Uganda , 2014, AIDS.
[19] N. Shaffer,et al. Is Option B+ the best choice? , 2013, The Lancet.
[20] B. Tran,et al. Determinants of antiretroviral treatment adherence among HIV/AIDS patients: a multisite study , 2013, Global health action.
[21] M. Siedner,et al. Higher Baseline CD4 Cell Count Predicts Treatment Interruptions and Persistent Viremia in Patients Initiating ARVs in Rural Uganda , 2013, Journal of acquired immune deficiency syndromes.
[22] H. Coovadia,et al. Is Option B+ the best choice? , 2013, The Lancet.
[23] Curtis Cooper,et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. , 2012, The Journal of infectious diseases.
[24] A. Ingram,et al. Governmentality and security in the US President’s Emergency Plan for AIDS Relief (PEPFAR) , 2010 .